Effect of menopausal hormone therapy on blood glucose in perimenopausal women with type 2 diabetes
Objective: To observe and analyze the influence of hormone replacement therapy on blood glucose of perimenopausal women with type 2 diabetes. Methods: Eighty-two perimenopausal patients with type 2 diabetes hospitalized in Second Hospital of Shijiazhuang during June 2014 to June 2016 were selected and randomly divided into an observation group (n=41) and a control group (n=41). Based on conventional hyperglycemic treatment, we applied Livial to the observation group while complex vitamin B for placebo treatment to the control group, and compared the clinical effect, blood glucose level, insulin resistance and relevant indexes. Results: The total effective rates of the observation group and the control group were 97.56% and 80.48% respectively, and the difference was statistically significant (χ2=6.116, P=0.013); the difference of pre-treatment levels of E2, FPG, 2hPG, HbAlc, HOMA-IR, resistin, TNF-α and CRP between two groups was not statistically significant (P>0.05); the post-treatment levels of FPG, 2hPG, HbAlc, HOMA-IR, resistin, TNF-α and CRP in the observation group decreased obviously, and compared with those before treatment, the difference was statistically significant (P<0.05); estrogen level increased slightly, but compared with that before treatment, the difference was not statistically significant (P>0.05); the variation of above indexes after treatment in the control group was not obvious, but compared with relevant indexes in the observation group after treatment, the difference was statistically significant (P<0.05). Conclusion: Adopting tibolone to treat perimenopausal type 2 diabetes patients can obviously reduce blood glucose with better therapeutic effect.